According to a recent LinkedIn post from Saluda Medical, pain specialist Dr. Eric Cornidez reports that many of his patients using the Evoke System are seeing stronger outcomes after permanent implant than during the initial trial phase. The post notes that Cornidez is a paid consultant, emphasizes that individual results may vary, and directs readers to risk and safety information for this prescription-only device.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn content underscores Evoke’s positioning in the spinal cord stimulation market as an option for chronic intractable pain in the trunk and limbs. For investors, the suggestion of durable or improving post-implant outcomes, if replicated broadly in real-world use, could support clinician adoption and reimbursement arguments, potentially strengthening Saluda Medical’s competitive stance within the chronic pain neuromodulation segment.